Clarity Pharmaceuticals (ASX:CU6) completed the dose escalation phase of its SECuRE trial, according to a Wednesday Australian bourse filing.
The safety review committee recommended that it proceed to the cohort expansion phase of the study at eight gigabecquerel dose level and increase the number of cycles from four to up to six.
The SECuRE trial assesses the safety and efficacy of the drug in the treatment of patients with metastatic castrate-resistant prostate cancer.
It said that across all cohorts of the dose escalation phase, 68% of the participants showed a reduction in prostate-specific antigen, despite 77% of the participants only receiving a single dose of copper-67-SAR-bisPSMA. It also showed a favorable safety profile across all cohorts.
The SECuRE trial protocol was amended to administer copper-67-SAR-bisPSMA to participants at earlier stages of the disease, in a pre-chemotherapy setting, incorporating an increase in the number of participants from 14 to 24, with a subset expected to receive a combination with enzalutamide.
The firm's shares rose 4% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。